Jeffrey Bennett
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neuromyelitis Optica | 81 | 2025 | 128 | 17.270 |
Why?
| Aquaporin 4 | 56 | 2025 | 96 | 9.190 |
Why?
| Multiple Sclerosis | 34 | 2025 | 437 | 6.180 |
Why?
| Autoantibodies | 51 | 2025 | 1465 | 5.240 |
Why?
| Immunoglobulin G | 52 | 2024 | 846 | 4.630 |
Why?
| Optic Neuritis | 15 | 2023 | 40 | 4.280 |
Why?
| B-Lymphocytes | 16 | 2024 | 823 | 2.370 |
Why?
| Myelin-Oligodendrocyte Glycoprotein | 17 | 2024 | 49 | 1.810 |
Why?
| Optic Nerve | 12 | 2023 | 65 | 1.700 |
Why?
| Optic Nerve Diseases | 5 | 2022 | 34 | 1.600 |
Why?
| Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 26 | 1.430 |
Why?
| Astrocytes | 14 | 2025 | 190 | 1.340 |
Why?
| Antibodies, Monoclonal, Humanized | 17 | 2024 | 764 | 1.340 |
Why?
| Neuroglia | 5 | 2024 | 167 | 1.080 |
Why?
| Antibodies, Monoclonal | 16 | 2023 | 1359 | 1.060 |
Why?
| Tomography, Optical Coherence | 7 | 2023 | 187 | 1.060 |
Why?
| Demyelinating Diseases | 7 | 2020 | 84 | 1.050 |
Why?
| Epitopes | 8 | 2025 | 466 | 0.910 |
Why?
| Humans | 140 | 2025 | 129126 | 0.900 |
Why?
| Retinal Degeneration | 2 | 2023 | 37 | 0.880 |
Why?
| Complement System Proteins | 7 | 2019 | 307 | 0.860 |
Why?
| Natalizumab | 4 | 2020 | 40 | 0.850 |
Why?
| Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 59 | 0.840 |
Why?
| Methylprednisolone | 1 | 2023 | 82 | 0.830 |
Why?
| Immunosuppressive Agents | 7 | 2022 | 690 | 0.820 |
Why?
| Optic Neuropathy, Ischemic | 4 | 2015 | 30 | 0.800 |
Why?
| Magnetic Resonance Imaging | 13 | 2025 | 3383 | 0.780 |
Why?
| Blood-Brain Barrier | 5 | 2022 | 129 | 0.770 |
Why?
| Autoimmunity | 4 | 2017 | 860 | 0.760 |
Why?
| Immunoglobulin Heavy Chains | 4 | 2015 | 80 | 0.750 |
Why?
| Immunotherapy | 4 | 2020 | 588 | 0.700 |
Why?
| Animals | 55 | 2023 | 34600 | 0.700 |
Why?
| Fingolimod Hydrochloride | 1 | 2020 | 36 | 0.700 |
Why?
| Cerebellum | 3 | 2018 | 217 | 0.690 |
Why?
| Brain | 8 | 2019 | 2628 | 0.670 |
Why?
| Disease Models, Animal | 15 | 2023 | 3953 | 0.660 |
Why?
| Complement Activation | 4 | 2022 | 365 | 0.640 |
Why?
| Complement C1q | 1 | 2019 | 38 | 0.630 |
Why?
| Plasma Cells | 7 | 2017 | 65 | 0.630 |
Why?
| Oligodendrocyte Precursor Cells | 1 | 2019 | 21 | 0.630 |
Why?
| Inflammation | 11 | 2023 | 2668 | 0.630 |
Why?
| Pseudotumor Cerebri | 2 | 2016 | 24 | 0.620 |
Why?
| Glial Fibrillary Acidic Protein | 5 | 2024 | 93 | 0.620 |
Why?
| Cell Membrane | 3 | 2017 | 722 | 0.610 |
Why?
| Aminopyridines | 1 | 2019 | 96 | 0.610 |
Why?
| Remyelination | 1 | 2018 | 14 | 0.610 |
Why?
| Papilledema | 4 | 2023 | 40 | 0.600 |
Why?
| Central Nervous System | 5 | 2023 | 255 | 0.600 |
Why?
| Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 73 | 0.590 |
Why?
| Pyrroles | 1 | 2019 | 192 | 0.590 |
Why?
| Herpesvirus 3, Human | 7 | 2015 | 330 | 0.580 |
Why?
| Organic Chemicals | 1 | 2019 | 128 | 0.580 |
Why?
| Immunologic Factors | 4 | 2022 | 229 | 0.570 |
Why?
| Microglia | 2 | 2019 | 228 | 0.570 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2017 | 57 | 0.560 |
Why?
| Glucocorticoids | 2 | 2019 | 575 | 0.560 |
Why?
| Disease Management | 2 | 2018 | 593 | 0.550 |
Why?
| CHO Cells | 8 | 2019 | 150 | 0.550 |
Why?
| Transverse Sinuses | 1 | 2016 | 8 | 0.540 |
Why?
| Adult | 41 | 2025 | 35512 | 0.540 |
Why?
| Spinal Cord | 8 | 2023 | 354 | 0.540 |
Why?
| Antigens, CD19 | 5 | 2022 | 115 | 0.540 |
Why?
| Retina | 5 | 2023 | 282 | 0.530 |
Why?
| Heat-Shock Proteins | 1 | 2017 | 131 | 0.530 |
Why?
| Cricetulus | 7 | 2019 | 104 | 0.530 |
Why?
| Mice | 30 | 2023 | 16644 | 0.530 |
Why?
| Diagnostic Techniques, Ophthalmological | 1 | 2016 | 38 | 0.530 |
Why?
| Recombinant Proteins | 8 | 2019 | 1284 | 0.520 |
Why?
| Myelin Sheath | 6 | 2023 | 161 | 0.520 |
Why?
| Biomarkers | 11 | 2025 | 3896 | 0.500 |
Why?
| Middle Aged | 38 | 2025 | 31079 | 0.500 |
Why?
| Mutagenesis | 2 | 2019 | 181 | 0.490 |
Why?
| Stents | 2 | 2016 | 504 | 0.470 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2006 | 95 | 0.470 |
Why?
| Herpesvirus 4, Human | 2 | 2012 | 151 | 0.460 |
Why?
| Giant Cell Arteritis | 5 | 2020 | 47 | 0.450 |
Why?
| Optic Atrophy | 2 | 2011 | 10 | 0.440 |
Why?
| Intracranial Hypotension | 2 | 2025 | 40 | 0.440 |
Why?
| Temporal Arteries | 4 | 2015 | 46 | 0.440 |
Why?
| Female | 55 | 2025 | 68517 | 0.430 |
Why?
| Peptide Fragments | 4 | 2023 | 686 | 0.410 |
Why?
| Antigens, Viral | 3 | 2015 | 174 | 0.410 |
Why?
| Flow Cytometry | 9 | 2023 | 1142 | 0.400 |
Why?
| Visual Acuity | 6 | 2021 | 322 | 0.400 |
Why?
| Axons | 2 | 2022 | 188 | 0.390 |
Why?
| Retinal Ganglion Cells | 3 | 2016 | 97 | 0.390 |
Why?
| Myelin Basic Protein | 6 | 2018 | 46 | 0.390 |
Why?
| Wolfram Syndrome | 1 | 2011 | 4 | 0.380 |
Why?
| Autoantigens | 5 | 2025 | 416 | 0.380 |
Why?
| Recurrence | 7 | 2023 | 1003 | 0.380 |
Why?
| Hemodynamics | 1 | 2016 | 1084 | 0.370 |
Why?
| Double-Blind Method | 8 | 2024 | 1865 | 0.370 |
Why?
| Central Nervous System Infections | 1 | 2011 | 35 | 0.370 |
Why?
| Cricetinae | 6 | 2019 | 275 | 0.370 |
Why?
| Organ Culture Techniques | 5 | 2018 | 144 | 0.360 |
Why?
| Gene Targeting | 1 | 2011 | 82 | 0.360 |
Why?
| Epstein-Barr Virus Infections | 1 | 2012 | 92 | 0.360 |
Why?
| Eye Diseases | 2 | 2020 | 79 | 0.360 |
Why?
| Nerve Degeneration | 1 | 2010 | 44 | 0.360 |
Why?
| Stilbenes | 1 | 2010 | 37 | 0.350 |
Why?
| Male | 41 | 2025 | 63201 | 0.350 |
Why?
| Nerve Regeneration | 1 | 2010 | 63 | 0.350 |
Why?
| Young Adult | 16 | 2024 | 12389 | 0.340 |
Why?
| Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 37 | 0.340 |
Why?
| Nerve Tissue Proteins | 3 | 2014 | 568 | 0.340 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 20 | 0.330 |
Why?
| Meningioma | 2 | 2023 | 81 | 0.330 |
Why?
| Mice, Inbred C57BL | 10 | 2023 | 5284 | 0.320 |
Why?
| Immune System Phenomena | 1 | 2009 | 2 | 0.320 |
Why?
| Rats | 12 | 2021 | 5173 | 0.320 |
Why?
| Adolescent | 18 | 2024 | 20301 | 0.320 |
Why?
| Virus Diseases | 1 | 2011 | 209 | 0.320 |
Why?
| Cell Survival | 2 | 2019 | 1077 | 0.310 |
Why?
| Amino Acid Sequence | 7 | 2015 | 2041 | 0.310 |
Why?
| Nervous System Diseases | 2 | 2020 | 254 | 0.310 |
Why?
| Rats, Inbred Lew | 7 | 2021 | 92 | 0.300 |
Why?
| Ophthalmology | 2 | 2007 | 82 | 0.290 |
Why?
| Immunoglobulins, Intravenous | 2 | 2022 | 130 | 0.290 |
Why?
| Neurology | 2 | 2007 | 104 | 0.290 |
Why?
| Protein Binding | 7 | 2025 | 2106 | 0.290 |
Why?
| Aged | 20 | 2025 | 22089 | 0.290 |
Why?
| Antibodies | 3 | 2017 | 391 | 0.280 |
Why?
| Neurodegenerative Diseases | 1 | 2009 | 110 | 0.280 |
Why?
| Peptide Library | 5 | 2025 | 85 | 0.280 |
Why?
| Oligoclonal Bands | 3 | 2011 | 20 | 0.270 |
Why?
| T-Lymphocytes | 3 | 2023 | 1924 | 0.270 |
Why?
| Immunization, Passive | 3 | 2020 | 85 | 0.270 |
Why?
| Nerve Fibers, Myelinated | 1 | 2006 | 43 | 0.270 |
Why?
| Mutation | 6 | 2019 | 3700 | 0.270 |
Why?
| Proteomics | 2 | 2012 | 1010 | 0.260 |
Why?
| Corpus Callosum | 1 | 2006 | 66 | 0.260 |
Why?
| Antibody Formation | 1 | 2007 | 288 | 0.260 |
Why?
| Herpes Zoster | 3 | 2015 | 317 | 0.250 |
Why?
| Atrophy | 2 | 2023 | 172 | 0.250 |
Why?
| Syndecan-1 | 4 | 2011 | 27 | 0.240 |
Why?
| B-Lymphocyte Subsets | 2 | 2024 | 75 | 0.240 |
Why?
| Immunodominant Epitopes | 2 | 2017 | 28 | 0.240 |
Why?
| Cell Adhesion Molecules | 1 | 2006 | 172 | 0.240 |
Why?
| Myasthenia Gravis | 2 | 2022 | 22 | 0.240 |
Why?
| Prospective Studies | 9 | 2024 | 7079 | 0.230 |
Why?
| Lupus Vasculitis, Central Nervous System | 1 | 2024 | 15 | 0.230 |
Why?
| Retrospective Studies | 11 | 2024 | 14571 | 0.230 |
Why?
| Acute Disease | 3 | 2018 | 968 | 0.230 |
Why?
| Genetic Diseases, Inborn | 1 | 2004 | 38 | 0.230 |
Why?
| Neurofilament Proteins | 1 | 2024 | 45 | 0.220 |
Why?
| Nystagmus, Pathologic | 1 | 2024 | 10 | 0.220 |
Why?
| Spastic Paraplegia, Hereditary | 1 | 2024 | 9 | 0.220 |
Why?
| Cerebellar Ataxia | 1 | 2024 | 10 | 0.220 |
Why?
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 28 | 0.220 |
Why?
| Diagnosis, Differential | 6 | 2023 | 1417 | 0.220 |
Why?
| Risk Assessment | 4 | 2021 | 3260 | 0.220 |
Why?
| Blindness, Cortical | 1 | 2003 | 5 | 0.220 |
Why?
| Proteoglycans | 1 | 2004 | 109 | 0.220 |
Why?
| Proteolipids | 1 | 2023 | 30 | 0.220 |
Why?
| Paraplegia | 1 | 2024 | 56 | 0.220 |
Why?
| Epitopes, T-Lymphocyte | 2 | 2016 | 185 | 0.210 |
Why?
| Oligodendroglia | 2 | 2017 | 166 | 0.210 |
Why?
| Enzyme Inhibitors | 1 | 2007 | 811 | 0.210 |
Why?
| Epitope Mapping | 4 | 2017 | 57 | 0.210 |
Why?
| White Matter | 1 | 2025 | 133 | 0.210 |
Why?
| Neuroprotection | 1 | 2023 | 34 | 0.210 |
Why?
| Seroconversion | 1 | 2023 | 46 | 0.210 |
Why?
| Immune System | 1 | 2004 | 177 | 0.210 |
Why?
| Vision Disorders | 2 | 2021 | 136 | 0.200 |
Why?
| Adrenocorticotropic Hormone | 1 | 2023 | 132 | 0.200 |
Why?
| Cells, Cultured | 7 | 2016 | 4010 | 0.200 |
Why?
| Lupus Erythematosus, Systemic | 2 | 2023 | 250 | 0.200 |
Why?
| Molecular Sequence Data | 5 | 2011 | 2819 | 0.190 |
Why?
| Mice, Transgenic | 5 | 2018 | 2079 | 0.190 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 466 | 0.190 |
Why?
| Leukocytes, Mononuclear | 2 | 2023 | 538 | 0.190 |
Why?
| Antibody Affinity | 2 | 2019 | 59 | 0.190 |
Why?
| Pre-Eclampsia | 1 | 2003 | 185 | 0.180 |
Why?
| Protein Isoforms | 4 | 2017 | 379 | 0.180 |
Why?
| Comorbidity | 2 | 2024 | 1547 | 0.180 |
Why?
| Autoimmune Diseases of the Nervous System | 1 | 2021 | 24 | 0.180 |
Why?
| Internationality | 2 | 2019 | 148 | 0.180 |
Why?
| Immunogenicity, Vaccine | 1 | 2020 | 27 | 0.180 |
Why?
| Lymphocyte Activation | 2 | 2020 | 1098 | 0.180 |
Why?
| Immunoglobulin Light Chains | 2 | 2015 | 40 | 0.170 |
Why?
| Receptors, Interleukin-6 | 1 | 2020 | 37 | 0.170 |
Why?
| Cell Proliferation | 3 | 2020 | 2347 | 0.170 |
Why?
| Azathioprine | 1 | 2020 | 49 | 0.170 |
Why?
| Interferon-gamma | 1 | 2023 | 762 | 0.170 |
Why?
| Antibodies, Blocking | 1 | 2019 | 33 | 0.170 |
Why?
| Myelin Proteins | 2 | 2017 | 44 | 0.160 |
Why?
| Viral Vaccines | 1 | 2020 | 94 | 0.160 |
Why?
| Prevalence | 2 | 2024 | 2564 | 0.160 |
Why?
| Steroids | 1 | 2020 | 148 | 0.160 |
Why?
| Treatment Outcome | 11 | 2024 | 10226 | 0.160 |
Why?
| Incidence | 2 | 2024 | 2635 | 0.160 |
Why?
| Models, Molecular | 3 | 2025 | 1483 | 0.160 |
Why?
| Cell Separation | 2 | 2015 | 313 | 0.160 |
Why?
| Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 14 | 0.160 |
Why?
| Intersectoral Collaboration | 1 | 2019 | 61 | 0.160 |
Why?
| Oxidoreductases | 1 | 2019 | 90 | 0.160 |
Why?
| S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 7 | 0.160 |
Why?
| Glutathione S-Transferase pi | 1 | 2018 | 9 | 0.160 |
Why?
| Cell Lineage | 1 | 2020 | 334 | 0.160 |
Why?
| Killer Cells, Natural | 3 | 2024 | 426 | 0.150 |
Why?
| Communicable Diseases | 1 | 2020 | 144 | 0.150 |
Why?
| Cognitive Dysfunction | 1 | 2023 | 347 | 0.150 |
Why?
| Peptides | 2 | 2019 | 911 | 0.150 |
Why?
| Myelin Proteolipid Protein | 1 | 2018 | 62 | 0.150 |
Why?
| Child | 12 | 2024 | 20805 | 0.150 |
Why?
| Animals, Newborn | 2 | 2018 | 805 | 0.150 |
Why?
| Immunoglobulin Variable Region | 3 | 2008 | 79 | 0.150 |
Why?
| Point Mutation | 1 | 2019 | 224 | 0.150 |
Why?
| SOXB1 Transcription Factors | 1 | 2018 | 58 | 0.150 |
Why?
| Mice, Knockout | 9 | 2017 | 2765 | 0.140 |
Why?
| Betacoronavirus | 1 | 2020 | 252 | 0.140 |
Why?
| Cohort Studies | 5 | 2022 | 5407 | 0.140 |
Why?
| Spatial Analysis | 1 | 2017 | 21 | 0.140 |
Why?
| Sphenoid Bone | 1 | 2017 | 15 | 0.140 |
Why?
| Skull Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 485 | 0.140 |
Why?
| Least-Squares Analysis | 1 | 2017 | 72 | 0.140 |
Why?
| Antibodies, Viral | 4 | 2023 | 603 | 0.140 |
Why?
| Oculomotor Muscles | 1 | 2017 | 38 | 0.140 |
Why?
| Orbital Diseases | 1 | 2017 | 28 | 0.140 |
Why?
| Albumins | 1 | 2017 | 101 | 0.130 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2023 | 847 | 0.130 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 97 | 0.130 |
Why?
| Microvessels | 1 | 2017 | 79 | 0.130 |
Why?
| Protein Structure, Secondary | 2 | 2015 | 338 | 0.130 |
Why?
| Follow-Up Studies | 3 | 2016 | 4915 | 0.130 |
Why?
| Fibrinogen | 1 | 2017 | 158 | 0.130 |
Why?
| Interleukin-6 | 1 | 2020 | 718 | 0.130 |
Why?
| Interferon-beta | 2 | 2025 | 87 | 0.130 |
Why?
| HEK293 Cells | 4 | 2022 | 687 | 0.130 |
Why?
| Microscopy, Confocal | 1 | 2017 | 309 | 0.130 |
Why?
| Aged, 80 and over | 8 | 2021 | 7065 | 0.130 |
Why?
| Ethics, Research | 1 | 2015 | 30 | 0.130 |
Why?
| Adrenal Cortex Hormones | 2 | 2021 | 519 | 0.130 |
Why?
| Herpes Zoster Ophthalmicus | 1 | 2015 | 5 | 0.120 |
Why?
| Eye Infections, Viral | 1 | 2015 | 6 | 0.120 |
Why?
| Treatment Failure | 1 | 2016 | 343 | 0.120 |
Why?
| Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| Microscopy, Fluorescence | 1 | 2017 | 402 | 0.120 |
Why?
| Coronavirus Infections | 1 | 2020 | 338 | 0.120 |
Why?
| Retinal Neurons | 1 | 2015 | 3 | 0.120 |
Why?
| Molecular Dynamics Simulation | 1 | 2017 | 217 | 0.120 |
Why?
| Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.120 |
Why?
| Scanning Laser Polarimetry | 1 | 2014 | 1 | 0.120 |
Why?
| Diffusion Tensor Imaging | 1 | 2015 | 73 | 0.120 |
Why?
| Plasma Exchange | 1 | 2014 | 12 | 0.120 |
Why?
| Protein Structure, Tertiary | 2 | 2015 | 836 | 0.120 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2011 | 3624 | 0.120 |
Why?
| Visual Pathways | 2 | 2007 | 51 | 0.120 |
Why?
| Small Molecule Libraries | 2 | 2013 | 86 | 0.120 |
Why?
| Nerve Fibers | 1 | 2015 | 88 | 0.120 |
Why?
| Nuclear Proteins | 1 | 2019 | 660 | 0.110 |
Why?
| Alanine | 1 | 2015 | 141 | 0.110 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 940 | 0.110 |
Why?
| Rats, Inbred F344 | 2 | 2012 | 251 | 0.110 |
Why?
| Glycine | 1 | 2015 | 165 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 1 | 2018 | 1945 | 0.110 |
Why?
| Erythropoietin | 1 | 2014 | 84 | 0.110 |
Why?
| Rats, Sprague-Dawley | 2 | 2016 | 2245 | 0.110 |
Why?
| Gene Expression Profiling | 1 | 2020 | 1689 | 0.110 |
Why?
| Placenta Diseases | 1 | 2013 | 14 | 0.110 |
Why?
| Peptoids | 1 | 2013 | 1 | 0.110 |
Why?
| Fetal Death | 1 | 2013 | 56 | 0.110 |
Why?
| Transcriptome | 2 | 2020 | 883 | 0.110 |
Why?
| Antibody Specificity | 2 | 2011 | 182 | 0.100 |
Why?
| Retinal Necrosis Syndrome, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| Biomedical Research | 1 | 2019 | 647 | 0.100 |
Why?
| Proteome | 2 | 2015 | 431 | 0.100 |
Why?
| Antineoplastic Agents | 1 | 2024 | 2060 | 0.100 |
Why?
| Computer Simulation | 1 | 2017 | 941 | 0.100 |
Why?
| Syndrome | 2 | 2019 | 337 | 0.100 |
Why?
| Phenotype | 3 | 2020 | 3058 | 0.100 |
Why?
| Cell Membrane Permeability | 1 | 2012 | 80 | 0.100 |
Why?
| Potassium Channels, Inwardly Rectifying | 1 | 2012 | 31 | 0.100 |
Why?
| Multiprotein Complexes | 2 | 2012 | 147 | 0.100 |
Why?
| Exanthema | 1 | 2013 | 73 | 0.100 |
Why?
| Antigens, CD20 | 2 | 2023 | 27 | 0.100 |
Why?
| Recombinant Fusion Proteins | 1 | 2015 | 634 | 0.100 |
Why?
| Area Postrema | 1 | 2011 | 1 | 0.100 |
Why?
| Drug Discovery | 1 | 2013 | 130 | 0.100 |
Why?
| Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 6 | 0.100 |
Why?
| Cranial Sinuses | 1 | 2011 | 13 | 0.100 |
Why?
| HLA-DRB1 Chains | 1 | 2012 | 108 | 0.100 |
Why?
| Pandemics | 1 | 2020 | 1491 | 0.100 |
Why?
| Endothelial Cells | 1 | 2017 | 701 | 0.100 |
Why?
| Excitatory Amino Acid Transporter 2 | 1 | 2011 | 15 | 0.100 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2011 | 28 | 0.100 |
Why?
| Fundus Oculi | 1 | 2011 | 61 | 0.090 |
Why?
| Mass Spectrometry | 1 | 2015 | 660 | 0.090 |
Why?
| Cerebral Angiography | 2 | 2011 | 109 | 0.090 |
Why?
| Quality of Life | 1 | 2023 | 2694 | 0.090 |
Why?
| Tissue Culture Techniques | 3 | 2017 | 68 | 0.090 |
Why?
| Fluorescein Angiography | 1 | 2011 | 143 | 0.090 |
Why?
| Integrin alpha4beta1 | 2 | 2010 | 7 | 0.090 |
Why?
| Vascular Diseases | 1 | 2013 | 236 | 0.090 |
Why?
| Neurosurgical Procedures | 1 | 2011 | 172 | 0.080 |
Why?
| Prognosis | 1 | 2018 | 3788 | 0.080 |
Why?
| Cell Line | 3 | 2011 | 2737 | 0.080 |
Why?
| Spinal Puncture | 1 | 2009 | 18 | 0.080 |
Why?
| Neurons | 4 | 2024 | 1456 | 0.080 |
Why?
| Research Design | 1 | 2015 | 1040 | 0.080 |
Why?
| Algorithms | 1 | 2017 | 1621 | 0.080 |
Why?
| Databases, Factual | 1 | 2015 | 1279 | 0.080 |
Why?
| Genes | 1 | 2009 | 226 | 0.080 |
Why?
| Brain Injuries | 1 | 2014 | 468 | 0.080 |
Why?
| Time Factors | 4 | 2015 | 6518 | 0.080 |
Why?
| Pregnancy Complications | 1 | 2013 | 491 | 0.080 |
Why?
| Blindness | 1 | 2008 | 37 | 0.080 |
Why?
| Optic Disk | 1 | 2008 | 40 | 0.070 |
Why?
| Case-Control Studies | 3 | 2024 | 3342 | 0.070 |
Why?
| Clone Cells | 3 | 2017 | 255 | 0.070 |
Why?
| Lipid Metabolism | 1 | 2011 | 493 | 0.070 |
Why?
| Polymorphism, Genetic | 1 | 2011 | 639 | 0.070 |
Why?
| Transfection | 3 | 2018 | 896 | 0.070 |
Why?
| Risk Factors | 3 | 2015 | 9768 | 0.070 |
Why?
| Antibody-Producing Cells | 1 | 2007 | 30 | 0.070 |
Why?
| Retinal Artery | 1 | 2007 | 16 | 0.070 |
Why?
| Age of Onset | 2 | 2020 | 494 | 0.070 |
Why?
| Vision, Low | 1 | 2007 | 16 | 0.070 |
Why?
| United States | 1 | 2024 | 13939 | 0.070 |
Why?
| Monitoring, Physiologic | 1 | 2009 | 268 | 0.070 |
Why?
| Molecular Biology | 2 | 2009 | 55 | 0.070 |
Why?
| Health | 1 | 2007 | 74 | 0.070 |
Why?
| Visual Fields | 1 | 2007 | 88 | 0.070 |
Why?
| Subacute Sclerosing Panencephalitis | 1 | 2006 | 5 | 0.070 |
Why?
| von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.070 |
Why?
| Measles virus | 1 | 2006 | 13 | 0.070 |
Why?
| Nucleocapsid Proteins | 1 | 2006 | 25 | 0.070 |
Why?
| Bevacizumab | 1 | 2007 | 131 | 0.070 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2007 | 90 | 0.070 |
Why?
| Puerperal Disorders | 1 | 2007 | 30 | 0.070 |
Why?
| Vitreous Body | 1 | 2007 | 105 | 0.070 |
Why?
| Binding, Competitive | 2 | 2019 | 199 | 0.060 |
Why?
| Cytotoxicity Tests, Immunologic | 2 | 2019 | 42 | 0.060 |
Why?
| Models, Immunological | 1 | 2006 | 94 | 0.060 |
Why?
| Angiogenesis Inhibitors | 1 | 2007 | 216 | 0.060 |
Why?
| Injections, Spinal | 2 | 2016 | 106 | 0.060 |
Why?
| Immunologic Memory | 1 | 2007 | 341 | 0.060 |
Why?
| Myelography | 1 | 2025 | 29 | 0.060 |
Why?
| Membrane Proteins | 1 | 2011 | 1109 | 0.060 |
Why?
| Fetus | 1 | 2009 | 760 | 0.060 |
Why?
| Cell Line, Tumor | 4 | 2015 | 3184 | 0.060 |
Why?
| Child, Preschool | 4 | 2021 | 10450 | 0.060 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2007 | 501 | 0.060 |
Why?
| DNA | 1 | 2011 | 1392 | 0.060 |
Why?
| Syndecans | 1 | 2004 | 4 | 0.060 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2006 | 254 | 0.060 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2025 | 70 | 0.060 |
Why?
| Complementarity Determining Regions | 1 | 2004 | 49 | 0.060 |
Why?
| Tomography, X-Ray Computed | 2 | 2025 | 2541 | 0.060 |
Why?
| Fistula | 1 | 2024 | 35 | 0.060 |
Why?
| Motor Neuron Disease | 1 | 2004 | 16 | 0.060 |
Why?
| Risk | 1 | 2007 | 856 | 0.060 |
Why?
| Ataxia | 1 | 2024 | 41 | 0.060 |
Why?
| Patient Selection | 1 | 2008 | 665 | 0.060 |
Why?
| Cranial Nerve Diseases | 1 | 2004 | 41 | 0.060 |
Why?
| Cryoelectron Microscopy | 1 | 2025 | 177 | 0.060 |
Why?
| Cerebrospinal Fluid Leak | 1 | 2024 | 47 | 0.060 |
Why?
| Granzymes | 1 | 2024 | 46 | 0.050 |
Why?
| Genetic Predisposition to Disease | 1 | 2012 | 2267 | 0.050 |
Why?
| Receptors, IgG | 1 | 2023 | 74 | 0.050 |
Why?
| Cytotoxicity, Immunologic | 1 | 2024 | 218 | 0.050 |
Why?
| Optic Nerve Neoplasms | 1 | 2023 | 12 | 0.050 |
Why?
| Headache | 1 | 2024 | 138 | 0.050 |
Why?
| Eye Abnormalities | 1 | 2002 | 11 | 0.050 |
Why?
| Feasibility Studies | 1 | 2006 | 862 | 0.050 |
Why?
| Developmental Biology | 1 | 2002 | 23 | 0.050 |
Why?
| Embryonic and Fetal Development | 1 | 2002 | 94 | 0.050 |
Why?
| Biopsy | 2 | 2017 | 1086 | 0.050 |
Why?
| Complement Inactivating Agents | 1 | 2023 | 45 | 0.050 |
Why?
| Genetic Techniques | 1 | 2002 | 64 | 0.050 |
Why?
| Extracellular Matrix Proteins | 1 | 2023 | 141 | 0.050 |
Why?
| Receptors, Cholinergic | 1 | 2022 | 37 | 0.050 |
Why?
| Disease Progression | 3 | 2021 | 2613 | 0.050 |
Why?
| Meningeal Neoplasms | 1 | 2023 | 93 | 0.050 |
Why?
| Antigens, Surface | 1 | 2022 | 150 | 0.050 |
Why?
| Eye | 1 | 2002 | 103 | 0.050 |
Why?
| Delphi Technique | 1 | 2023 | 226 | 0.050 |
Why?
| Fluorescent Antibody Technique | 2 | 2013 | 374 | 0.050 |
Why?
| Binding Sites | 2 | 2017 | 1241 | 0.050 |
Why?
| Glycoproteins | 1 | 2023 | 337 | 0.050 |
Why?
| Evoked Potentials, Visual | 1 | 2021 | 35 | 0.050 |
Why?
| Encephalitis Viruses, Tick-Borne | 1 | 2020 | 8 | 0.040 |
Why?
| Base Sequence | 1 | 2004 | 2135 | 0.040 |
Why?
| Sensitivity and Specificity | 1 | 2025 | 1825 | 0.040 |
Why?
| COS Cells | 2 | 2011 | 184 | 0.040 |
Why?
| Random Allocation | 1 | 2021 | 346 | 0.040 |
Why?
| Consensus | 1 | 2023 | 638 | 0.040 |
Why?
| Immunity, Humoral | 1 | 2020 | 117 | 0.040 |
Why?
| Immunomodulation | 1 | 2020 | 89 | 0.040 |
Why?
| Cross-Sectional Studies | 2 | 2024 | 5070 | 0.040 |
Why?
| Pregnancy | 3 | 2013 | 6375 | 0.040 |
Why?
| Stiff-Person Syndrome | 1 | 2019 | 12 | 0.040 |
Why?
| Models, Biological | 1 | 2007 | 1695 | 0.040 |
Why?
| Carrier Proteins | 1 | 2023 | 732 | 0.040 |
Why?
| Serum | 1 | 2019 | 57 | 0.040 |
Why?
| Rituximab | 1 | 2020 | 163 | 0.040 |
Why?
| Disability Evaluation | 1 | 2021 | 291 | 0.040 |
Why?
| Glutamate Decarboxylase | 1 | 2019 | 168 | 0.040 |
Why?
| Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2018 | 48 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2021 | 864 | 0.040 |
Why?
| Survival Analysis | 1 | 2021 | 1265 | 0.040 |
Why?
| Antirheumatic Agents | 1 | 2020 | 282 | 0.040 |
Why?
| Sequence Alignment | 2 | 2009 | 330 | 0.040 |
Why?
| Protein Conformation, alpha-Helical | 1 | 2017 | 15 | 0.040 |
Why?
| Reproducibility of Results | 1 | 2025 | 3033 | 0.030 |
Why?
| Clonal Deletion | 1 | 2017 | 16 | 0.030 |
Why?
| Recovery of Function | 1 | 2021 | 648 | 0.030 |
Why?
| Self Tolerance | 1 | 2017 | 26 | 0.030 |
Why?
| Immunoglobulin Class Switching | 1 | 2017 | 18 | 0.030 |
Why?
| Hydrogen Bonding | 1 | 2017 | 149 | 0.030 |
Why?
| Craniotomy | 1 | 2017 | 70 | 0.030 |
Why?
| Analysis of Variance | 2 | 2011 | 1271 | 0.030 |
Why?
| Amino Acid Motifs | 1 | 2017 | 209 | 0.030 |
Why?
| Protein Interaction Domains and Motifs | 1 | 2017 | 137 | 0.030 |
Why?
| Lipid Bilayers | 1 | 2017 | 97 | 0.030 |
Why?
| Phosphatidylcholines | 1 | 2017 | 146 | 0.030 |
Why?
| Animals, Outbred Strains | 1 | 2015 | 3 | 0.030 |
Why?
| Th17 Cells | 1 | 2016 | 82 | 0.030 |
Why?
| Protein Multimerization | 1 | 2017 | 178 | 0.030 |
Why?
| Chronic Disease | 1 | 2022 | 1707 | 0.030 |
Why?
| Influenza Vaccines | 1 | 2020 | 536 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 816 | 0.030 |
Why?
| Neoplasm Invasiveness | 1 | 2017 | 480 | 0.030 |
Why?
| Cell Death | 1 | 2017 | 348 | 0.030 |
Why?
| Histocompatibility Antigens Class II | 1 | 2017 | 360 | 0.030 |
Why?
| Leukocytes | 1 | 2016 | 303 | 0.030 |
Why?
| Cerebral Arterial Diseases | 1 | 2015 | 44 | 0.030 |
Why?
| Thermodynamics | 1 | 2017 | 406 | 0.030 |
Why?
| Spinal Cord Diseases | 1 | 2014 | 41 | 0.030 |
Why?
| Spleen | 1 | 2016 | 513 | 0.030 |
Why?
| Immune Tolerance | 1 | 2016 | 349 | 0.030 |
Why?
| Calcium Signaling | 1 | 2016 | 235 | 0.030 |
Why?
| CD59 Antigens | 1 | 2014 | 20 | 0.030 |
Why?
| Nogo Proteins | 1 | 2013 | 9 | 0.030 |
Why?
| Cell Adhesion Molecules, Neuronal | 1 | 2014 | 39 | 0.030 |
Why?
| Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 20 | 0.030 |
Why?
| Sodium Channels | 1 | 2014 | 63 | 0.030 |
Why?
| Age Factors | 1 | 2021 | 3120 | 0.030 |
Why?
| Parkinson Disease | 1 | 2019 | 462 | 0.030 |
Why?
| Narcolepsy | 1 | 2013 | 21 | 0.030 |
Why?
| Autoimmune Diseases | 1 | 2016 | 425 | 0.030 |
Why?
| Immunoglobulin Idiotypes | 1 | 2012 | 27 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 5 | 0.030 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2015 | 224 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2013 | 168 | 0.020 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2017 | 703 | 0.020 |
Why?
| Molecular Docking Simulation | 1 | 2012 | 109 | 0.020 |
Why?
| Surface Plasmon Resonance | 1 | 2012 | 88 | 0.020 |
Why?
| Cerebral Cortex | 1 | 2015 | 423 | 0.020 |
Why?
| Binding Sites, Antibody | 1 | 2012 | 42 | 0.020 |
Why?
| Vaccination | 1 | 2020 | 1349 | 0.020 |
Why?
| Phlebography | 1 | 2011 | 36 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2019 | 2716 | 0.020 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 231 | 0.020 |
Why?
| O Antigens | 1 | 2011 | 9 | 0.020 |
Why?
| Injections, Intravenous | 1 | 2011 | 193 | 0.020 |
Why?
| Structure-Activity Relationship | 1 | 2012 | 531 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2019 | 2739 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2011 | 206 | 0.020 |
Why?
| Mice, Mutant Strains | 1 | 2011 | 292 | 0.020 |
Why?
| Tissue Distribution | 1 | 2011 | 291 | 0.020 |
Why?
| Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| High-Throughput Screening Assays | 1 | 2012 | 136 | 0.020 |
Why?
| Ligands | 1 | 2013 | 614 | 0.020 |
Why?
| Microfilament Proteins | 1 | 2011 | 125 | 0.020 |
Why?
| Pilot Projects | 1 | 2016 | 1567 | 0.020 |
Why?
| Embryo, Mammalian | 1 | 2011 | 226 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2015 | 1000 | 0.020 |
Why?
| Tubulin | 1 | 2011 | 138 | 0.020 |
Why?
| Calcium-Binding Proteins | 1 | 2011 | 211 | 0.020 |
Why?
| Biological Assay | 1 | 2010 | 118 | 0.020 |
Why?
| Palmitic Acid | 1 | 2009 | 40 | 0.020 |
Why?
| Hospitalization | 1 | 2019 | 2077 | 0.020 |
Why?
| Quantum Dots | 1 | 2009 | 36 | 0.020 |
Why?
| Diagnostic Techniques, Neurological | 1 | 2009 | 9 | 0.020 |
Why?
| Antiviral Agents | 1 | 2015 | 706 | 0.020 |
Why?
| Water | 1 | 2012 | 444 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2013 | 1671 | 0.020 |
Why?
| Pyrazoles | 1 | 2012 | 405 | 0.020 |
Why?
| Immunoglobulins | 1 | 2009 | 157 | 0.020 |
Why?
| Microscopy, Electron, Transmission | 1 | 2009 | 142 | 0.020 |
Why?
| Virion | 1 | 2009 | 85 | 0.020 |
Why?
| Protein Kinase C | 1 | 2009 | 253 | 0.020 |
Why?
| Genetic Markers | 1 | 2009 | 339 | 0.020 |
Why?
| Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| Databases, Genetic | 1 | 2009 | 228 | 0.020 |
Why?
| Enzyme Activation | 1 | 2009 | 799 | 0.020 |
Why?
| Alzheimer Disease | 1 | 2013 | 518 | 0.020 |
Why?
| Protein Processing, Post-Translational | 1 | 2009 | 450 | 0.020 |
Why?
| DNA, Viral | 1 | 2009 | 348 | 0.020 |
Why?
| Glioma | 1 | 2010 | 354 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2009 | 1230 | 0.020 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2012 | 1048 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2008 | 758 | 0.020 |
Why?
| Cytokines | 1 | 2013 | 1987 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 1353 | 0.010 |
Why?
| Trochlear Nerve Diseases | 1 | 2004 | 7 | 0.010 |
Why?
| Oculomotor Nerve Diseases | 1 | 2004 | 10 | 0.010 |
Why?
| Abducens Nerve Diseases | 1 | 2004 | 12 | 0.010 |
Why?
| Infant | 1 | 2017 | 8992 | 0.010 |
Why?
| Sequence Analysis, DNA | 1 | 2006 | 773 | 0.010 |
Why?
| Evidence-Based Medicine | 1 | 2008 | 718 | 0.010 |
Why?
| Calcium | 1 | 2009 | 1180 | 0.010 |
Why?
| Gene Expression Regulation | 1 | 2011 | 2508 | 0.010 |
Why?
| Computational Biology | 1 | 2006 | 598 | 0.010 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2008 | 1363 | 0.010 |
Why?
| Practice Guidelines as Topic | 1 | 2008 | 1493 | 0.010 |
Why?
| Signal Transduction | 1 | 2009 | 4838 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2004 | 5377 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|